Martínez SC

Language: Spanish
References: 10
Page: 131-135
PDF size: 42.98 Kb.

ABSTRACT

Reperfusion therapy is fundamental in the treatment of the acute myocardial infarct and can be accomplished either through pharmacological methods or through direct angioplasty. Undoubtedly, pharmacological reperfusion is the most available and it has modified the natural history of the acute myocardial infarct. Reperfusion therapy must be as dynamic and multifactorial as the physiopathology per se of the acute myocardial infarct. Reperfusion is defined as: to reestablish blood flow after an obstruction has been caused and to be useful it must be close to normal both in the epicardial and transmyocardial vessels.

REFERENCES

1. ISIS-2. (Second international study of infarct survival). Collaborative group. Randomized trial of intravenous streptokinase, oral aspirin. Both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1990, 336: 65-71.

2. The Gusto investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.

3. WHITE HD, VAN DE WERF FJJ: New frontiters: Thrombolysis for acute myocardial infarction. Circulation 1998; 97:1632-1646.

4. C MARTÍNEZ SÁNCHEZ, C MARTÍNEZ L, ALBERTO LASES, H GONZÁLEZ P, E CHUQUIURE V, U JUÁREZ HERRERA, E LUPI: Análisis del tiempo de reperfusión entre angioplastía primaria y trombólisis. Éxito vs tiempo. Arch Inst Cardiol Mex 1999; 69: 438-444.

5. MUKHERJEE D, MOLITERNO D: Achieving tissuelevel perfusion in the setting of acute myocardial infarction. Am J Cardiol 2000; 85: 39C-46C.

6. ELLIOT M, ANTMAN MD; ROBERT P, GIUGLIANO, MD, SM; C MICHAEL GIBSON, MS, MD; CAROLYN H, MCCABE, BS; PATRICK COUSSEMENT, MD; NEAL S KLEIMAN, MD; ALEC VAHANIAN, MD; AA JENNIFER ADGEY, MD; IAN MENOWN, MD; HANS-JURGEN RUPPRECHT, MD; R VAN DER WIEKEN, MD; JOHN DUCAS, MD; JOEL SCHERER, MD; KEAVEN ANDERSON, PHD; FRANS VAN DE WERF, MD, PHD: Abciximab facilite the rate and extent of thrombolysis o rejolt of the trombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999: 2720- 2732.

7. THOMAS J RYAN, JEFFREY L ANDERSON, ELLIOT M ANTMAN, BLAINE A BRANIFF, NEIL H BROOKS, ROBERT M CALIFE, L DAVID HILLIS, LOREN F HIRATZKA, ELLIOT RAPAPORT, BARBARA J RIEGEL, RICHARD O RUSSELL, EARLE SMITH III, W DOUGLAS WEAVER: Guías para el tratamiento de los pacientes con infarto del miocardio. Grupo de trabajo. American College of Cardiology/American heart Association. JACC 1996; 28: 1328-428.

8. COHEN M, DEMERS C, GURFINKEL EP, TURPIE AG, FROMELL GJ, GOODMAN S, LANGER A, CALIFF RM, FOX KA, PREMMEREUR J, BIGONZI F: Essence Group. Primary end point analysis from essence trial: Enoxaparin vs unfractionated heparin in unstable angina and non- Q wave infarction. Circulation 1996; 94 (Suppl I): 554.

9. HERRMANN HC: Triple therapy for acute myocardial infarction: Combining fibrinolysis, platelet IIb/IIIa. Inhibition, and percutaneous coronary intervention. Am J Cardiol 2000; 85: 10C-16C.

10. C MICHAEL GIBSON, MS, MD; CHISTOPHER P, CANNON, MD; SABINA A, MURPHY, MPH; KATHRYN A, RYAN, BS; REBECCA MESLEY, BS; SUSAN J MARBLE, RN, MS; CAROLYN H, MCCABE, BS; FRANS VAN DE WERF, MD, PHD; EUGENE BRAUNWALD, MD: Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolityc drugs. Circulation 2000; 101: 125-130.